New malaria pill matches current gold standard in large trial
NCT ID NCT05842954
First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 21 times
Summary
This study tested a new malaria drug, KLU156, against the standard treatment Coartem in over 1,700 adults and children with uncomplicated malaria. The goal was to see if KLU156 works just as well and is safe. Results showed KLU156 is non-inferior to Coartem, offering a potential new option for treating malaria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Banfora, Burkina Faso
-
Novartis Investigative Site
Bobo-Dioulasso, 01, Burkina Faso
-
Novartis Investigative Site
Nanoro, BP 18, Burkina Faso
-
Novartis Investigative Site
Ouagadougou, 11 BP 218, Burkina Faso
-
Novartis Investigative Site
Sabou, 06 BP 10248, Burkina Faso
-
Novartis Investigative Site
Abidjan, 13BP972, Côte d’Ivoire
-
Novartis Investigative Site
Agboville, BP 154, Côte d’Ivoire
-
Novartis Investigative Site
Azaguié, BP 173, Côte d’Ivoire
-
Novartis Investigative Site
Kimpese, Bas-Congo Province, Democratic Republic of the Congo
-
Novartis Investigative Site
Kisantu, Bas-Congo Province, Democratic Republic of the Congo
-
Novartis Investigative Site
Lubumbashi, Du Haut Katanga, 7010, Democratic Republic of the Congo
-
Novartis Investigative Site
Kenge, Kwango, Democratic Republic of the Congo
-
Novartis Investigative Site
Masi-Manimba, Kwilu, Democratic Republic of the Congo
-
Novartis Investigative Site
Lambaréné, BP 242, Gabon
-
Novartis Investigative Site
Libreville, BP 1437, Gabon
-
Novartis Investigative Site
Kintampo, 92037, Ghana
-
Novartis Investigative Site
Navrango, VWJ6+8WF, Ghana
-
Novartis Investigative Site
Kombewa, 40102, Kenya
-
Novartis Investigative Site
Nairobi, 00200, Kenya
-
Novartis Investigative Site
Siaya, 2300, Kenya
-
Novartis Investigative Site
Sotouba, Mali
-
Novartis Investigative Site
Niamey, 8003, Niger
-
Novartis Investigative Site
Gicumbi, Northern Province, 00114, Rwanda
-
Novartis Investigative Site
Kigali, 0000, Rwanda
-
Novartis Investigative Site
Kigali, BP 4560, Rwanda
-
Novartis Investigative Site
Rubavu, Rwanda
-
Novartis Investigative Site
Rusizi, Rwanda
-
Novartis Investigative Site
Bagamoyo, Tanzania
-
Novartis Investigative Site
Korogwe Tanga, Tanzania
-
Novartis Investigative Site
Tanga, 5004, Tanzania
-
Novartis Investigative Site
Tororo, 10102, Uganda
-
Novartis Investigative Site
Nchelenge, Luapula Province, 70100, Zambia
-
Novartis Investigative Site
Ndola, 71769, Zambia
Conditions
Explore the condition pages connected to this study.